Will cosentyx increased prostate specific antigen levels in humans?

Short answer: No. There isn’t evidence that cosentyx (secukinumab) increases prostate-specific antigen (PSA) levels in humans.

What we know:
- In the pivotal clinical trials for plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis, PSA elevations were not reported as a safety issue with secukinumab.
- The product labeling does not list PSA monitoring or PSA elevation as a known adverse effect.
- PSA can rise for many unrelated reasons (age, prostatitis, benign prostatic hyperplasia, prostate cancer, recent procedures). An elevated PSA should be evaluated by a clinician, regardless of secukinumab use.

If you have a specific concern (elevated PSA, prostate cancer risk, or symptoms), discuss it with your healthcare provider. They can review your history and determine if any testing or monitoring is appropriate.

If you’d like, I can summarize study findings or provide references to trial data related to secukinumab’s safety.